Menarini and OBT conduct Phase I oncology trial of MEN1309
Italian pharmaceutical company Menarini Ricerche has partnered with UK-based biotechnology firm Oxford BioTherapeutics (OBT) to conduct a Phase I clinical trial of MEN1309 to treat patients with metastatic solid cancers and non-Hodgkin ’s lymphoma (NH…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer | Cancer & Oncology | Clinical Trials | Italy Health | Lymphoma | Men | Pharmaceuticals